Calman Prussin, M.D., Joins Knopp Biosciences To Lead Clinical Development Of Dexpramipexole In Eosinophilic Asthma

PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC announced today that Calman Prussin, M.D., formerly a senior investigator in eosinophil-associated inflammatory diseases at the National Institutes of Health and the outgoing chair of the American Board of Allergy and Immunology, has joined Knopp to head clinical and translational medicine in immunology.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.